In Brief: Immunomedics' CEA-Scan
This article was originally published in The Gray Sheet
Lilly will distribute the colorectal cancer imaging agent in Europe after Immunomedics terminates its 1995 and 1996 marketing and distribution arrangements with Mallinckrodt for the U.S. and Europe. A new distributor for the U.S. will be announced soon, the Morris Plains, New Jersey-based company says. Immunomedics is pursuing a different strategy to promote the product, which requires a "focused effort to educate and train both oncologists and nuclear physicians," the company says...
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.